entertainment -WSS

entertainment

author：hotspot 2025-09-06 04:30:35 - browse：7

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： What do new weight loss drugs mean for bariatric surgery?

explore

WSS

Future doctors need a strong humanities education

Winners, losers from Medicare’s list of drugs subject to price talks

Flu vaccine reformulation won't be easy, manufacturers warn

Head of FDA's diagnostics center, who led through Covid, retires

Study finds new variant for Parkinson’s in African populations

Apellis safety probe of eye disease drug centers on injection needle

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

How one medical school became remarkably diverse

As pharma fights Medicare drug negotiation, hospitals, docs silent

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How Long Island became the ‘eugenics capital of the world’

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Winners, losers from Medicare’s list of drugs subject to price talks

Drug repurposing or repositioning? The language matters

NYU Langone launches private ChatGPT for its health care data

Peter Hotez and the public health issue of online harassment

AstraZeneca bets AAV gene therapy will still deliver the goods

focus

Mass General, Mayo Clinic look to monetize custom

Medicare explains how it will choose drugs for negotiation

Head of FDA's diagnostics center, who led through Covid, retires

AstraZeneca bets AAV gene therapy will still deliver the goods

HPV vaccine, cervical cancer study delivers historic results

TikTok, Instagram influencers need more rules for drug ads

knowledge

explore

explore

focus